GlassScriptPhysician profile
Beth A Lewis
NPI 1205457264
$3,546.86
in general payments reported to CMS, 2019-2025
18 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.81 · 2023: $330 · 2024: $1,117 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.11 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $689.31 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $468.46 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $388.97 | 2023-2025 | Glassia |
| Glaxosmithkline, LLC. | $379.01 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $317.22 | 2023-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $272.80 | 2024-2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $219.96 | 2025 | Lumryz |
| Verona Pharma, INC. | $136.54 | 2025 | Ohtuvayre |
| Genzyme Corporation | $125.06 | 2024-2025 | |
| United Therapeutics Corporation | $124.44 | 2024-2025 | Remodulin, Orenitram, Remodulin |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Inari Medical, INC. | $86.87 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pulmonx Corporation | $78.09 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $60.77 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $29.81 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $25.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.86 | 2023 | |
| Axsome Therapeutics, INC. | $19.93 | 2023 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.